From Early Innovation to Industry Recognition: A Map of Dalton Venture's Specialized and Innovative Portfolio Companies
"Specialized, refined, distinctive, and innovative" enterprises are increasingly becoming a key benchmark for assessing the growth quality of China's technology and innovation companies. It represents not only a company's technical strength, innovation capability, and growth potential in niche sectors, but also serves as external validation from the industrial system of the value of outstanding SMEs. Recently, **Xuanyu Medical**, a **Dalton Venture family company**, was once again named to **Shanghai's second batch of 2026 specialized, refined, distinctive, and innovative SMEs. This marks Xuanyu Medical's continued recognition following its 2023 selection.
Background
"Specialized, refined, distinctive, and innovative" — China's "zhuanjingtexin" designation — is increasingly becoming a key benchmark for assessing the quality of growth among Chinese technology innovators. It signals not just technical strength, innovation capacity, and growth potential in niche domains, but also serves as external validation from the industrial system of a promising SME's value. Recently, Dalton Venture portfolio company Xuanyu Medical was once again named to Shanghai's second batch of 2026 zhuanjingtexin SMEs. This marks Xuanyu Medical's successful re-certification after first receiving the designation in 2023.
As of August 2026, 24 of Dalton Venture's 70+ portfolio companies have received national or provincial zhuanjingtexin recognition, including 10 designated as national-level "Little Giants" and 7 achieving dual provincial-plus-national certification. These companies span medical devices, biotechnology, medical AI, new materials, semiconductors, and intelligent manufacturing, among other fields. This recognition from industry stakeholders serves as external validation of Dalton Venture's long-standing commitment to "investing early, investing small, and investing in hard tech."
Long-term validation from industry
The zhuanjingtexin enterprise cultivation system is a critical institutional mechanism for advancing high-quality development among Chinese SMEs. Progressing from innovative SMEs to provincial zhuanjingtexin status, and ultimately to national-level "Little Giant" designation, requires continuous breakthroughs across specialization, refinement, differentiation, and innovation capabilities.
Dalton Venture focuses on innovation opportunities in life sciences and hard tech. The concentration of its portfolio companies within this system represents cross-validation from industry: confirmation of their technical moats, market position, and growth quality within niche domains.
Four directions, a snapshot of hard tech growth
01
Medical devices and high-end diagnostic equipment
A long-standing focus area for Dalton Venture, this sector typically demands extended R&D cycles and industrial validation. Zhuanjingtexin recognition reflects sustained accumulation in core technology, product capability, and market competitiveness.
Among national "Little Giants," Dalton portfolio companies Our United Corporation and BlueRayMed focus on high-end medical equipment; Hanno Medical has advanced to the forefront of extracorporeal life support; HC Scientific enters life science tools through automation equipment. Provincial designees include DeepWise, New Cloud Medical, StarSea, Zhongboruikang, Xuanyu Medical, Anjiechang Medical, and Oushisheng, each occupying distinct niche segments.
02
Biopharma and biomanufacturing
From biotechnology platforms to innovative drug R&D to biomanufacturing commercialization, an expanding cohort of companies is driving industrial upgrading through foundational technology innovation.
Dalton portfolio company Huyuan Biotechnology was named a national "Little Giant" in 2025; MolBreeding received recognition for its molecular breeding technology; Triastek explores new paradigms in pharmaceutical manufacturing; Anaerobic Bio, VitaVitro Biotech, Boruice Bio, Kangweijian, and Shenyun Medical comprise the provincial tier.
03
AI + life sciences
From medical imaging analysis to cytopathology diagnosis to intelligent medical devices, AI is becoming critical infrastructure for medical innovation.
Dalton portfolio company Lanting Intelligent Medicine was named a national "Little Giant" as early as 2021, with sustained exploration of AI applications in healthcare; DeepWise focuses on medical imaging AI technology to advance AI-assisted diagnosis and treatment; Bingjing Yizhi and others continue progressing through provincial designations.
04
Hard tech materials and semiconductors
Hard tech innovation occurs not only in end products but also in breakthroughs in foundational materials, core components, and manufacturing capabilities.
In hard tech materials and semiconductors, Dalton portfolio companies Dongrui New Materials and SENSILICON represent national-level players in new materials and chips, respectively.
Geographically, these 24 companies are distributed across Shanghai, Beijing, Shenzhen, Chengdu, Xi'an, Tianjin, Hangzhou, and Wuhan — the zhuanjingtexin map tracing China's hard tech industrial belts.
Why zhuanjingtexin?
The core pillars of zhuanjingtexin align closely with Dalton Venture's enduring investment logic:
Focus — sustained deep cultivation of a niche domain
Refinement — continuous improvement of product and industrialization capabilities
Differentiation — building distinctive competitive advantages
Innovation — achieving breakthroughs through proprietary technology
At the early investment stage, companies may lack mature business models or established market positions. Yet truly valuable technology enterprises often already demonstrate clear technical direction and team capabilities. Dalton Venture targets precisely these early-stage innovators with the potential to become segment leaders.
Zhuanjingtexin recognition is not an investment objective, but rather a milestone of industry validation along a company's growth trajectory.
Growing alongside exceptional companies
Technology innovation is a long-distance race. From laboratory breakthroughs to scaled industrial application; from early founding teams to segment-leading enterprises — growth takes time, and it takes long-term partnership.
Time validates technological value, and time reveals the answer to long-termism. To date, Dalton Venture has invested in over 70 life science and hard tech innovation companies. Going forward, Dalton Venture will continue seeking out innovation teams oriented toward future industries, built on core technology, and possessing long-term growth potential — accompanying more Chinese technology enterprises deeper into industry.
ID: daltonventure
Long press to follow
Recommended Reading
